Beneficial effects of early administration of recombinant human B-type natriuretic peptide in ST-elevation myocardial infarction patients receiving percutaneous coronary intervention treatment

What Was Tested

This randomized controlled trial paper looks at BNP (Nesiritide).

The researchers aimed to evaluate the clinical performance of early administration of recombinant human B-type natriuretic peptide (rhBNP) to ST-elevation myocardial infarction (STEMI) patients receiving percutaneous coronary intervention (PCI) treatment.

Who Took Part

According to the abstract, 185 patients were involved.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

In total, 185 patients diagnosed with STEMI were enrolled and randomised into either the placebo-treated (n = 88) or rhBNP-treated (n = 97) group.

Patients were given either saline or rhBNP ten minutes before PCI and monitored with various cardiac parameters, including accelerated idioventricular rhythm, frequent ventricular premature beat (FVPB), ventricular tachycardia, systolic blood pressure, thrombolysis in myocardial infarction (TIMI) 3 gradation, corrected TIMI frame count (cTFC) and myocardial blush grade (MBG) 3 classification.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Some patients received a placebo instead of BNP (Nesiritide), giving a reference point.

What Was Measured

PubMed files the paper under topics including Arrhythmias, Cardiac, Coronary Circulation, Electrocardiography, Hypotension, Natriuretic Peptide, Brain, Percutaneous Coronary Intervention and Recombinant Proteins.

Author keywords: anterior wall myocardial infarction, coronary blood flow, reperfusion injury and rhBNP.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of BNP (Nesiritide) in 185 patients.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (Singapore medical journal), a journal based in India.

More context: the BNP (Nesiritide) compound page, all human trials.